Explanation:
Mainly by submerged fermentation using Aspergillus niger or Candida sp from different sources of carbohydrates, such as molasses and starch based.
B. It is a small pilot study on non-AWAR species.
C. It is a teaching activity that uses students' personally owned dogs and cats.
D. There are no circumstances in which animal work may begin before IACUC approval.
Answer: the correct option is D (There are no circumstances in which animal work may begin before IACUC approval)
Explanation:
The IACUC known as Institutional Animal Care and Use Committees is a local working group that research facilities must appoint in accordance with the Animal Welfare Act , Policy on Human Care and Use of Laboratory Animals. It was introduced to research system by the U.S. government in 1986. The policy protects all warm-blooded animals except rats, mice, and birds bred for research. For an institution to use a specie that is covered by the policy, it must obtain their approval before work begins. I hope this helps. Thanks.
b. identical copies.
c. separated during mitosis.
d. made during the S phase.
e. All of the above.
Answer:
The correct answer is e. All of the above.
Explanation:
Sister chromatids are made during the synthesis phase of the cell cycle. In the synthesis phase, the homologous chromosomes get replicated and sister chromatids are produced so they are produced by duplication of chromosomes.
As sister chromatids are produced by replication, therefore, they are identical copies of parent chromosomes. These sister chromatids are joined to each other at centromere. They get separated during the anaphase of mitosis and moves to the opposite pole.
Therefore the right answer is e.
A consumer is obtaining carbon by absorbing it from the soil.
A consumer is obtaining carbon by eating carbon-based molecules stored in a producer.
A consumer is obtaining carbon by eating carbon-based molecules stored in a decomposer.
Answer:
A
Explanation:
trust goes both ways
Answer:
Mixed inhibition refers to the combination of two reversible types of enzyme inhibition, competitive inhibition and non-competitive inhibition. The term mixed is used when the inhibitor can bind both the free enzyme and the enzyme-substrate complex. In mixed inhibition the inhibitor is in a different place from the active site where the substrate is found.
Mathematically, mixed inhibition occurs when both alpha and alpha-prime factors (introduced in the Michaelis-Menten equation representing competitive and non-competitive inhibition respectively) are present (they are larger than unity).
In a special case of mixed inhibition, the alpha and alpha-prime factors are the same, then non-competitive inhibition occurs.
With this type of inhibition Km depends on the affinity of the inhibitor to join E or ES and Vmax decreases.
Enzymatic inhibitors are molecules that bind enzymes and decrease their activity. Since blocking an enzyme can kill a pathogen or correct a metabolic imbalance, many medications act as enzyme inhibitors. They are also used as herbicides and pesticides. However, not all molecules that bind to enzymes are inhibitors; Enzymatic activators bind to enzymes and increase their activity.
The binding of an inhibitor can prevent the substrate from entering the active site of the enzyme and / or hinder the enzyme from catalyzing its corresponding reaction. The inhibitor binding may be reversible or irreversible. Normally, irreversible inhibitors react with the enzyme covalently and modify their chemical structure to the level of essential residues necessary for enzymatic activity. In contrast, reversible inhibitors bind to the enzyme in a non-covalent manner, resulting in different types of inhibitions, determined whether the inhibitor binds to the enzyme, the enzyme-substrate complex or both.
Many medications are enzymatic inhibitors, so their discovery and improvement is an active field of research in biochemistry and pharmacology. The validity of a medicinal enzyme inhibitor is usually determined by its specificity (its inability to bind to other proteins) and its potency (its dissociation constant, which indicates the concentration necessary to inhibit an enzyme). A high specificity and potency ensures that the medication will have few side effects and therefore a low toxicity.
b. Combine the cloned CFRT gene with a disarmed respiratory virus.
c. Clone the CFRT gene from someone with cystic fibrosis.
d. Clone the CFRT gene from someone without cystic fibrosis.
e.Modify the CFRT gene by putting on a different promoter
f. Test the patient’s blood cell DNA with PCR to see if they have the CFRT transgene.
g. Have the patient use an inhaler that contains the modified respiratory virus.
Answer:
d-b-g-f
Explanation:
1. Clone the CFRT gene from someone without cystic fibrosis.
This will make millions of copies of the gene (wild type, not being mutated and thus unable of producing the disease).
2. Combine the cloned CFRT gene with a disarmed respiratory virus.
This step will allow the virus to transport the gene of interest.
4. Have the patient use an inhaler that contains the modified respiratory virus.
This step helps the virus to enter and infect the patient's cells and thus allowing the copies of the transgene to be integrated into the patient's genome.
3. Test the patient's blood cell DNA with PCR to see if they have the CFRT transgene.
This will confirm if the transgene has actually been integrated into patient's genome.
The strand of RNA leaves the nucleus.
A protein is produced.
A strand of RNA is made from a strand of DNA.
The strand of RNA moves to the ribosome.
✔ 4
The DNA double helix unzips.
✔ 1
The strand of RNA leaves the nucleus.
✔ 3
A protein is produced.
✔ 5
A strand of RNA is made from a strand of DNA.
✔ 2